Brand & Manufacturer VerifiedUnited States
Elanco Animal Health Incorporated
Elanco
Elanco Animal Health is a top-tier global animal health company that has undergone a dramatic strategic transformation since its 2018 spin-off from Eli Lilly. Headquartered in Greenfield, Indiana, USA, the company generated USD 4.715 billion in 2025 revenue (up 6% reported, 7% organic), employing 9,300 employees across 17 manufacturing sites. Elanco is in the midst of a historic innovation renaissance—all six of its promised "Big 6" potential blockbuster drugs have been successfully delivered to market, including the JAK inhibitor Zenrelia (penetrating 50% of US clinics) and IL-31 mAb Befrena, which together generated $8.92 billion in 2025 innovation revenue.
Strengths:
• Innovation Pipeline Execution: All six "Big 6" blockbuster candidates successfully commercialized, including Zenrelia (JAK inhibitor) achieving 50% US clinic penetration within months
• Companion Animal Focus: Pet Health segment contributing $23B—nearly half of total revenue—driven by dermatology, parasiticide, and OA pain franchises
• Strategic Portfolio Rationalization: Sale of aquaculture business to Merck for $1.29B and divestiture of three underperforming manufacturing sites are sharpening operational focus
• Restructuring Discipline: "Elanco Ascend" program targeting $200-250M in annual EBITDA savings by 2030 through facility optimization and SG&A streamlining
• Global Diversification: Operations spanning 90+ countries with manufacturing facilities across four continents providing regional supply chain resilience
Weaknesses:
• Profitability Headwinds: Reported net loss of $2.32B in 2025 due to $1.75B in restructuring charges and significant intangible asset amortization from historical acquisitions
• Elevated Leverage: Net debt-to-adjusted EBITDA ratio of 3.6x, requiring disciplined deleveraging to regain full financial flexibility
• Manufacturing Transition Risk: Simultaneous divestiture of three facilities (Brazil, Kansas, UK) while launching six new products creates complex supply chain coordination challengesRead More ▼Show Less ▲
Strengths:
• Innovation Pipeline Execution: All six "Big 6" blockbuster candidates successfully commercialized, including Zenrelia (JAK inhibitor) achieving 50% US clinic penetration within months
• Companion Animal Focus: Pet Health segment contributing $23B—nearly half of total revenue—driven by dermatology, parasiticide, and OA pain franchises
• Strategic Portfolio Rationalization: Sale of aquaculture business to Merck for $1.29B and divestiture of three underperforming manufacturing sites are sharpening operational focus
• Restructuring Discipline: "Elanco Ascend" program targeting $200-250M in annual EBITDA savings by 2030 through facility optimization and SG&A streamlining
• Global Diversification: Operations spanning 90+ countries with manufacturing facilities across four continents providing regional supply chain resilience
Weaknesses:
• Profitability Headwinds: Reported net loss of $2.32B in 2025 due to $1.75B in restructuring charges and significant intangible asset amortization from historical acquisitions
• Elevated Leverage: Net debt-to-adjusted EBITDA ratio of 3.6x, requiring disciplined deleveraging to regain full financial flexibility
• Manufacturing Transition Risk: Simultaneous divestiture of three facilities (Brazil, Kansas, UK) while launching six new products creates complex supply chain coordination challenges
United StatesFounded 19549,300USD$4.7 B17 manufacturing sites globally / 100
Listed onNYSEELAN
Listed market data
ELAN · NYSE · weeklyHistory →- Market cap
- $11.8 B
- Share price
- USD 23.55
- 1Y change
- +9.9%
- Recent change
- -0.7%
- IPO price
- -6.2%
- Revenue (TTM)
- $5 B
10-22 → 10-23
USD 24.00 · from 9/20/2018
Revenue FY 2026 · updated 2026-10-23Source ↗
Financial history
Full market historyMonthCloseMarket capChange
- 2026-10USD 23.55$11.8 B+5.2%
- 2026-09USD 22.39$11.7 B-6.4%
- 2026-08USD 23.92$12.5 B-9.3%
- 2026-07USD 26.37$13.8 B+7.2%
- 2026-06USD 24.61$12.9 B+3.2%
- 2026-05USD 23.85$12.5 B+6.6%
- 2026-04USD 22.37$11.7 B-6.5%
- 2026-03USD 23.93$12.5 B-9.4%
- 2026-02USD 26.40$13.8 B+9.6%
- 2026-01USD 24.08$12.6 B+6.4%
- 2025-12USD 22.63$11.8 B-2.8%
- 2025-11USD 23.27$12.2 B—
Monthly closes · 2025-11 – 2026-10 · Full market history
In the press
All coverage →5 latest headlines12- Elanco Animal Health Inc (ELAN) Shares Fall 3.4% -- What GF Scor - GuruFocuswww.gurufocus.com2026-10-20
- Elanco Animal Health Slides as Analyst Downgrade Pressures Shares - Quiver Quantitativewww.quiverquant.com2026-10-20
- Form 4 Elanco Animal Health For: Oct 16 Filed by: Modi Rajeev A. - StreetInsiderwww.streetinsider.com2026-10-20
- An executive receives 62.7147 stock units in an Elanco (ELAN) award priced at $23.55 per unit. - Stock Titanwww.stocktitan.net2026-10-20
- Jefferies downgrades Elanco Animal Health stock rating on pricing risks - Investing.comwww.investing.com2026-10-20
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.
Elanco Animal Health, spun off from Eli Lilly in 2018, operates a hybrid manufacturing model combining heavy in-house production with strategic CDMO partnerships. The company maintains 17 core manufacturing sites across four continents, covering biologics fermentation UK Speke legacy capacity, oral solid dosage France Huningue, API and formulation synthesis China Wuxi, and advanced vaccine R&D/manufacturing Canada PEI and Germany Cuxhaven.
Under the "Elanco Ascend" productivity initiative targeting $200-250 million in EBITDA savings by 2030, the company is strategically streamlining: exiting three underutilized facilities (Brazil Belford Roxo closed; Kansas Shawnee and UK Speke sold to CDMO TriRx with long-term supply agreements), while concentrating investment in its Indianapolis OneHealth Innovation Lab and expanding US-based manufacturing to mitigate tariff risks and accelerate FDA/USDA approvals.
Under the "Elanco Ascend" productivity initiative targeting $200-250 million in EBITDA savings by 2030, the company is strategically streamlining: exiting three underutilized facilities (Brazil Belford Roxo closed; Kansas Shawnee and UK Speke sold to CDMO TriRx with long-term supply agreements), while concentrating investment in its Indianapolis OneHealth Innovation Lab and expanding US-based manufacturing to mitigate tariff risks and accelerate FDA/USDA approvals.
Companion Animal Portfolio — Core Business
• Dermatology: Zenrelia JAK inhibitor / Befrena IL-31 mAb
• Parasiticides: Credelio / Interceptor Plus
• Pain & Osteoarthritis: Galliprant
• Vaccines and specialty therapeutics
• Livestock and poultry health products
• Dermatology: Zenrelia JAK inhibitor / Befrena IL-31 mAb
• Parasiticides: Credelio / Interceptor Plus
• Pain & Osteoarthritis: Galliprant
• Vaccines and specialty therapeutics
• Livestock and poultry health products
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $4.7 B | −$232 M |
| 2024 | $4.4 B | $338 M |
| 2023 | $4.4 B | −$1.2 B |
| 2022 | $4.4 B | −$78 M |
| 2021 | $4.8 B | −$483 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Greenfield, Indiana, United States
Founded
1954
Employees
9,300
Revenue
USD$4.7 B (2025)
Market cap
$11.8 B
Factories
17 manufacturing sites globally
Listing
NYSE: ELAN
Categories
10 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: ELAN , Elanco Official Website
SEC EDGAR — Elanco Filings
Wikipedia — Elanco